Nuron Biotech, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nuronbiotech.com
A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers
Phase 2
- Conditions
- Infectious Disease
- Interventions
- Biological: NU300Biological: ActHIBBiological: Prevnar 13
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Nuron Biotech Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT01732198
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Phase 3
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Biological: NU100Biological: PlaceboBiological: rhIFN beta-1b
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Nuron Biotech Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT01464905
© Copyright 2025. All Rights Reserved by MedPath